Keywords
How to Cite
Abstract
Therapy of patients with cutaneous melanoma is a serious problem, since this disease is characterized by chemo and radioresistance. In addition, new effective drugs of targeted and immunotherapy are expensive. To be able to introduce new technologies, an assessment of the economic burden caused by the disease is necessary. The aim of the study was to systematize and summarize the data of modern literature on the costs of treatment for cutaneous melanoma. The review includes data from foreign and domestic articles found in the PubMed and elibrary.ru databases containing information on the economic burden of melanoma. The paper presents data on the cost of melanoma in different countries. The dependence of treatment costs on the methods of therapy used, the stage of the disease, the presence of adjuvant therapy, the number of metastatic sites, etc. is discussed. It has been shown that the costs of treating cutaneous melanoma are significant in all countries. The most expensive is the management of patients with unresectable or metastatic melanoma. Modern drugs of targeted and immunotherapy lead to significantly higher costs than chemotherapy drugs. Among the total costs, important components are the costs for adjuvant therapy and the managing of adverse events.References
Белоусов Д.Ю., Чеберда А.Е., Афанасьева Е.В., Гладков О.А. Клинико-экономический анализ применения ингибиторов рецептора PD-1 и комбинаций ингибиторов BRAF и МЕК для лечения метастатической меланомы с мутацией в гене BRAF V600// Качественная клиническая практика. 2018; 2: 13-28. [Belousov DYu, Cheberda AE, Afanasyeva EV, Gladkov OA. Clinico-economic analysis of PD-1 inhibitors and combinations of BRAF and MEK inhibitors for the treatment of metastatic melanoma with a BRAF V600 gene mutation. Kachestvennaya klinicheskaya praktika. 2018; 2: 13-28. (In Russ.) ]. DOI: 10.24411/25880519-2018-10041
Жуковец А.Г Современные принципы и перспективы лечения меланомы кожи //Онкологический журнал. 2015; 9 (4):69-76. [Zhukovets AG. Current concepts and prospects for skin melanoma management. Onkologicheskij zhurnal. 2015; 9 (4):69-76. (In Russ.)].
Каприн А.Д., Старинский В. В., Петрова Г. В. Злокачественные новообразования в России в 2016 году (заболеваемость и смертность) М.: МНИОИ им. П.А. Герцена филиал ФГБУ "НМИЦ радиологии" Минздрава России, 2018. 250 с. [Kaprin A.D., Starinskij V. V., Petrova G. V. Zlokachestvennye novoobrazovaniya v Rossii v 2016 godu (zabolevaemost> i smertnost>) M.: MNIOI im. P.A. Gercena filial FGBU "NMIC radiologii" Minzdrava Rossii, 2018. 250 s. (In Russ.)]
Ассоциация специалистов по проблемам меланомы: цели, задачи, направления деятельности //Эффективная фармакотерапия. 2016; 39: 6-7. [Associaciya specialistov po problemam melanomy: celi, zadachi, napravleniya deyatel'nosti. Effektivnaya farmakoterapiya. 2016; 39: 6-7. (In Russ.)].
Шаров С.В., Леонов М.Г. Перспективы лекарственного лечения меланомы кожи //Эффективная фармакотерапия. 2018; 25: 50-53. [Sharov SV, Leonov MG. Prospects for Melanoma of the Skin Drug Treatment. Effektivnaya farmakoterapiya. 2018; 25: 50-53. (In Russ.)].
Корман Д.Б. Эволюция лекарственной терапии меланомы //Вопросы онкологии. 2017; 63(3): 358-367. [Korman DB. Evolution of drug therapy for melanoma. Voprosy onkologii. 2017; 63(3): 358-367. (In Russ.)].
Полякова К. И., Холовня-Волоскова М. Э., Бяхов М. Ю., Ермолаева Т. Н., Фисун А. Г, Дубовцева В. А., Олюшина Е. М., Давыдовская М. В., Кокушкин К. А. Сравнительный анализ стоимости лекарственной терапии самых высокозатратных онкологических заболеваний в городе Москве //Злокачественные опухоли. 2018; 8(2): 12-20. DOI: 10.18027/2224-5057-2018-8-2-12-20
Grange F., Mohr P, Harries M. et al. Economic burden of advanced melanoma in France, Germany and the UK: a retrospective observational study (Melanoma Burden-of-Illness Study). Melanoma Res. 2017 Dec; 27(6):607-618. DOI: 10.1097/CMR.0000000000000372
Tarhini A., Ghate S.R., lonescu-Ittu R. et al. Postsurgical treatment landscape and economic burden of locoregional and distant recurrence in patients with operable nonmetastatic melanoma. Melanoma Res. 2018 Dec;28(6):618-628. DOI: 10.1097/CMR.0000000000000507
Zhang Y, Le T.K., Shaw J.W., Kotapati S. Retrospective analysis of drug utilization, health care resource use, and costs associated with IFN therapy for adjuvant treatment of malignant melanoma. Clinicoecon Outcomes Res. 2015 Jul 21;7:397-407. DOI: 10.2147/CE0R.S78704
Toy E.L., Vekeman F., Lewis M.C. et al. Costs, resource utilization, and treatment patterns for patients with metastatic melanoma in a commercially insured setting. Curr Med Res Opin. 2015 Aug;31(8):1561-72. DOI: 10.1185/03007995.2015.1062356
McArthur G.A., Mohr P, Ascierto PA. et al. Health Care Resource Utilization and Associated Costs Among Metastatic Cutaneous Melanoma Patients Treated with Ipilimumab (INTUITION Study). Oncologist. 2017 Aug;22(8):951-962. DOI: 10.1634/theoncologist.2016-0272
Reyes C., DaCosta Byfield S., Linke R. et al. The burden of metastatic melanoma: treatment patterns, healthcare use (utilization), and costs. Melanoma Res. 2013 Apr;23(2):159-66. DOI: 10.1097/CMR.0b013e32835e58d6
Ben ina G., Buljan M., itum M. et al. Health and Economic Burden of Skin Melanoma in Croatia - Cost-of-illness Study. Acta Dermatovenerol Croat. 2017; 25(1):1-7
Elliott T.M., Whiteman D.C., Olsen C.M., Gordon L.G. Estimated Healthcare Costs of Melanoma in Australia Over 3 Years Post-Diagnosis. Appl Health Econ Health Policy. 2017; 15(6):805-816. DOI: 10.1007/s40258-017-0341-y
Buja A., Sartor G., Scioni M. et al. Estimation of Direct Melanoma-related Costs by Disease Stage and by Phase of Diagnosis and Treatment According to Clinical Guidelines. Acta Derm Venereol. 2018; 98(2):218-224. DOI: 10.2340/00015555-2830
Wehler E., Zhao Z., Pinar Bilir S. et al. Economic burden of toxicities associated with treating metastatic melanoma in eight countries. Eur J Health Econ. 2017;18(1):49-58. DOI: 10.1007/s10198-015-0757-y
Chang C.L., Schabert V.F., Munakata J. et al. Comparative healthcare costs in patients with metastatic melanoma in the USA. Melanoma Res 2015;25:312-20.
Ghate S.R., Li Z., Tang J., Nakasato A.R. Economic Burden of Adverse Events Associated with Immunotherapy and Targeted Therapy for Metastatic Melanoma in the Elderly. Am Health Drug Benefits. 2018;11(7):334-343.
Mennini F.S., Bini C., Marcellusi A., Del Vecchio M. Cost Estimate of Immune-Related Adverse Reactions Associated with Innovative Treatments of Metastatic Melanoma. Clin Drug Investig. 2018 Oct;38(10):967-976. DOI: 10.1007/s40261-018-0690-9
Johnston K., Levy A.R., Lorigan P et al. Economic impact of healthcare resource utilisation patterns among patients diagnosed with advanced melanoma in the United Kingdom, Italy, and France: results from a retrospective, longitudinal survey (MELODY study). Eur J Cancer 2012;48:2175-82.
Copley-Merriman C, Stevinson K, Liu FX, Wang J, Mauskopf J, Zimovetz EA, Chmielowski B. Direct costs associated with adverse events of systemic therapies for advanced melanoma: Systematic literature review. Medicine (Baltimore). 2018 Aug;97(31):e11736. DOI: 10.1097/MD.0000000000011736
Игнатьева В.И., Деркач Е.В., Омельяновский В.В., Авксентьева М.В. Социально-экономическое бремя злокачественных новообразований в Российской Федерации // Медицинские технологии. Оценка и выбор. 2013; 4: 73-80. [Ignatyeva VI, Derkach EV, Omelyanovsky W, Avxentyeva Mv. The social and economic burden of cancer in the Russian Federation. Medicinskie tekhnologii. Ocenka i vybor. 2013; 4: 73-80. (In Russ.)].
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
© АННМО «Вопросы онкологии», Copyright (c) 2020